CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Targeted Proteomics in a Nutshell

Targeted Proteomics in a Nutshell

Applications of Proteomics in Medicine

Applications of Proteomics in Medicine

The Functioning of a Mass Spectrometry

The Functioning of a Mass Spectrometry

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Targeted Proteomics in a Nutshell

Targeted Proteomics in a Nutshell

Applications of Proteomics in Medicine

Applications of Proteomics in Medicine

The Functioning of a Mass Spectrometry

The Functioning of a Mass Spectrometry

Achieving trial master file quality, timeliness and completeness

Achieving trial master file quality,...

Antibodies: The Building Blocks of Cures

Antibodies: The Building Blocks of Cures

The Dynamic Commercial Aspects of Life Sciences

The Dynamic Commercial Aspects of...

The Future of Life Sciences Industry

The Future of Life Sciences Industry

Accelerating Digital Transformation through an Agile, Customer-centric Approach

Accelerating Digital Transformation...

Role of Targeted Proteomics in Antibody Response

Life Sciences Review | Thursday, February 10, 2022
Tweet

In order to determine variant-specific SARS-CoV-2 antibody response, quantitative, multiplexed, and specific target proteomics were used


FREMONT CA: The world’s fastest and largest worldwide immunization campaigns were developed and implemented due to the introduction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses. However, the loss of immunity over time, as well as the introduction of many SARS-CoV-2 variants of concern (VOCs), underscores the need for more accurate testing to assess the need for and timing of booster vaccinations. Although first-generation tests were widely used, it was discovered that they overestimated the true protective immunity against VOCs. Current neutralizing antibody (NAb) measurement technologies have been proven to have low clinical value. In contrast, serological approaches (ELISA or ECLIA) have been found to quantify only a portion of the antibody response.


A new study published in the pre-print server medRxiv* developed a "bait and capture" system, followed by multiplexed and targeted proteomic liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses for comparing immune correlates in response to vaccination, natural infection, and protection against VOCs.


The present research included serum samples from the COVIDsortium study, which had already undergone longitudinal immunological examination.Twenty-five healthcare workers (HCWs) with previous laboratory evidence of wild-type SARS-CoV-2 infection and twenty-six HCWs with no SARS-CoV-2 infection participated in the study. After that, an immunocomplex assay for SARS-CoV-2 was performed, followed by immunocomplex protein digestion.


Immunoglobulins IgG1, 2, 3 & 4, IgA1, IgM, and complement factors C1q, C4b, and C9 were found in serum samples from SARS-CoV-2 positive HCWs. Except for the Beta version, increasing exposure to SARS-CoV-2 VOCs increased the immunocomplex. As a result, the current study was able to show antibody responses in non-hospitalized healthcare workers three weeks after immunization. The LC-MS/MS multiplex assay was developed to be easily converted into clinical laboratory settings, even though it is a research standard assay. To gain a better understanding of the changing antibody-mediated immune response to SARS-CoV-2, more research is needed to evaluate the influence of antibody response over time, the severity of infection from different variations, and the change in immunocomplex with age.


Weekly Brief

loading
Top 10 Proteomics Solutions Companies 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/role-of-targeted-proteomics-in-antibody-response-nwid-730.html